Results 251 to 260 of about 18,639,208 (342)

P114: Over-representation of PMS2CL pseudogene interference in PMS2 testing in a non-European cohort

Genetics in Medicine Open
Emily Maxwell, Ayanna Boyce, Caitlin Reid, Ashley Marsh, Kevin Beezhold, Timothy Komala, Katie Lang, Marcy Richardson, Colby Chase   +8 more
doaj   +1 more source

Correction to "Clinical Pharmacology Perspective on Direct-To-Subcutaneous Dosing of T Cell Engagers in Oncology First-In-Human Studies". [PDF]

Clin Transl Sci
europepmc   +1 more source

Fatal Steam Pop Complicating Investigational SESAME Transcatheter Myotomy Using Off-the-Shelf Equipment. [PDF]

Circ Cardiovasc Interv
Lederman RJ, Greenbaum AB, Halaby RN, Stine AM, Khan JM, Bruce CG, Rogers T, Gleason PT, Bilen O, Babaliaros VC.   +9 more
europepmc   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Determinants of proclivity for anaesthesia as a career among medical students in a Southwestern Nigeria tertiary institution: a cross-sectional study. [PDF]

BMC Med Educ
Bolatito BA, Uche-Orji CI, Oyedokun AO, Chufor SH, Olatunde EO, Adesola AA, Idowu O.   +6 more
europepmc   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Book review. Interest Rate Modelling

, 2009
Howls, Chris
core  

Investigating the Appeal of Nicotine Pouch Packaging, Flavour, and Nicotine Descriptors Among Adults in the UK: An Online Experiment. [PDF]

Nicotine Tob Res
Taylor E, Ebdon M, Nottage M, Simonavicius E, Brose L, McNeill A, Arnott D, Cheeseman H, Bunce L, East K.   +9 more
europepmc   +1 more source

The Influence of Interest Groups on State Legislative Behavior

, 2011
Shannon Jenkins
openalex   +2 more sources